drug
cyclophosphamide
Marketedupdated 5mo agoby Long Grove Pharmaceuticals LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagDLBCL6 co-mentions · 3 sources
- tagOncology5 co-mentions · 4 sources
- tagCLL4 co-mentions · 1 sources
- companySandoz Inc2 co-mentions · 1 sources
- tagHematology2 co-mentions · 1 sources
- companyCity of Hope1 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
- companyGeneral Hospital of the People's Liberation Army1 co-mentions · 1 sources
indications
investigational
Breast CancerDLBCL
all catalysts(3)
phase 1 2 completion · 2
Trials studying cyclophosphamide
- phase2Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
- phase2Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
- phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- phase2A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
- phase1Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
- phase2Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- phase2A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
- phase2Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 26, 2035
~8.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Feb 15, 2036formulationUS 10993952
- Feb 15, 2036formulationUS 10993952
- Feb 15, 2036formulationUS 10993952
- Feb 15, 2036formulationUS 12329767
- Feb 15, 2036formulationUS 12329767
- Feb 15, 2036formulationUS 12329767
- Dec 1, 2035formulationUS 11382923
- Dec 1, 2035formulationUS 11382923
- Dec 1, 2035formulationUS 11382923
- Jul 13, 2035formulationUS 10849916
- Jul 13, 2035formulationUS 10849916
- Jul 13, 2035formulationUS 10849916
- Jun 26, 2035formulationUS 9662342
- Jun 26, 2035formulationUS 9662342
- Jun 26, 2035formulationUS 9662342
News(4)
- Sunny Pharmtech, Inc. Issues Voluntary Nationwide Recall of Cyclophosphamide for Injection, USP to the User Level Due to the Presence of Particulate MatterJuly 24, 2026 - Taoyuan City, Taiwan - Sunny Pharmtech, Inc is voluntarily recalling three lots of Cyclophosphamide for Injection, USP, 1g/vial and 2g/vial, to the User Level due to the presence of…fda_medwatch · 2mo ago
- Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast CancerTreatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.onclive · 5mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 5mo ago
- Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer CongressExperts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.onclive · 5mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that